Incidence and clinical course of thrombus formation on atrial septal defect and patent foramen ovale closure devices  by Schräder, Rainer
We find the results of Krumsdorf et al. (1) to be of
interest in its detail of the natural course of unusual
device-related, large-burden thrombosus in the now un-
common setting of protamine use. We consider other
associative relationships, as well as the editorial recommen-
dations of Moore and Levi (2), to be unsubstantiated.
Clinicians should not base management decisions in pa-
tients with PFO and stroke on such anecdotal and highly
selected data. We await the results of ongoing and future
randomized clinical trials to address these concerns.
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Incidence and Clinical Course of Thrombus
Formation on Atrial Septal Defect
and Patent Foramen Ovale Closure Devices
Krumsdorf et al. (1) present impressive data concerning the
risk of thrombus formation on closure devices for atrial
septal defects (ASDs) and patent foramen ovale (PFO) in
1,000 consecutive patients.
The vast majority of these patients were treated in the
Bethanien-Hospital where we worked together with Dr.
Sievert from July 1995 until he left our institution in June
2003. Until October 27, 2000, we shared the scientific
database for all patients who had received an atrial septal
implant. Therefore, we would like to add some information
on two of our patients who were apparently included in the
series of Krumsdorf et al. (1).
One PFO patient with an Amplatzer (AGA Medical
Corp., Golden Valley, Minnesota) occluder developed
thrombus on the left atrial disk of the device, which was
detected by transesophageal echocardiography (TEE) five
weeks after implantation (implanted January 26, 2000; TEE
date March 1, 2000). With heparinization and anticoagu-
lation, the further course was uneventful.
Another PFO patient suffered two strokes 5.7 years after
implantation of a Buttoned device (Custom Medical De-
vices, Amarillo, Texas). The TEE revealed a 10  7-mm
thrombus on the left atrial disk of the occluder (implanta-
tion date March 4, 1996; TEE date November 16, 2001).
The thrombus resolved after heparinization and anticoagu-
lation, and the further clinical course was uneventful. The
latter event was published as a case report (2).
We believe that these data might be clinically relevant,
not only because thrombus formation may occur early after
implantation of an Amplatzer device, but more importantly,
even after more than five years following defect closure.
Therefore, all investigators involved in the field of interven-
tional ASD closure have the obligation to follow their (own)
patients for an unlimited period of time.
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REPLY
We greatly appreciate the comments and suggestions by
Drs. Landzberg and colleagues, Massimo and colleagues,
Jux and Bertram, and Schräder regarding our recent paper
(1).
First, we absolutely share the opinion of Landzberg and
colleagues that randomized trials are superior to nonran-
domized trials! Conversely, nonrandomized trials are better
than no trials at all! And before a randomized trial can be
initiated we have to have an idea about what we are looking
for and what the incidence of a specific event like thrombus
formation might be. Dr. Landzberg and his colleagues know
very well how difficult it is to conduct a randomized trial in
catheter closure of intracardiac defects. Although the first
transcatheter atrial septal defect (ASD) closure was per-
formed more than 25 years ago, until today no randomized
trial has ever been started.
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